UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 19, 2006
(Date of earliest event reported)
LABORATORY CORPORATION
OF
AMERICA HOLDINGS
| DELAWARE | 1-11353 | 13-3757370 | ||
| (State or other jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA |
27215 | 336-229-1127 | ||
| (Address of principal executive offices) | (Zip Code) |
(Registrant's telephone number including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
On September 19, 2006, Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), announced today that for the period of September 12, 2006 to March 11, 2007, its $744 million in zero coupon subordinated Liquid Yield Option™ Notes (LYONs) due 2021 will, subject to the terms of the LYONs, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a LYON for the five trading days ended September 7, 2006, in addition to the continued accrual of the original issue discount.
Exhibits
99.1 Press Release dated September 19, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Laboratory Corporation of America Holdings (Registrant) |
||||
| Date: September 20, 2006 | By: | /s/Bradford T. Smith | ||
| Bradford T. Smith, Executive Vice President and Secretary |
||||
Exhibit 99.1
Laboratory Corporation of
America® Holdings
358 South Main Street
Burlington, NC 27215
Telephone:(336) 584-5171
FOR IMMEDIATE RELEASE
Investor Contact: Scott Fleming - 336-436-4879
Media Contact: Pam Sherry - 336-436-4855
Shareholder Direct: (800)LAB-0401
Company Information: www.LabCorp.com
LABCORP’S LIQUID
YIELD OPTIONTM NOTES
TO ACCRUE CONTINGENT
CASH INTEREST
Burlington, NC, September 19, 2006 — Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of September 12, 2006 to March 11, 2007, its $744 million in zero coupon subordinated Liquid Yield Option™ Notes (LYONs) due 2021 will, subject to the terms of the LYONs, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a LYON for the five trading days ended September 7, 2006, in addition to the continued accrual of the original issue discount.
About LabCorp
Laboratory Corporation of
America® Holdings, a S&P 500 company, is a pioneer in commercializing new
diagnostic technologies and the first in its industry to embrace genomic testing. With
annual revenues of $3.3 billion in 2005, approximately 24,000 employees nationwide, and
more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood
analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical
testing technology with its Centers of Excellence: The Center for Molecular Biology and
Pathology, in Research Triangle Park, NC; National Genetics Institute, Inc. in Los
Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN; The Center for Esoteric
Testing in Burlington, NC; DIANON Systems, Inc. based in Stratford, CT; US LABS based in
Irvine, CA; and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry
Associates laboratories. LabCorp clients include physicians, government agencies, managed
care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more
about our growing organization, visit our Web site at: www.LabCorp.com.
Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp’s financial results is included in the Company’s Form 10-K for the year ended December 31, 2005, and subsequent SEC filings.